Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $26.05, but opened at $27.28. Capricor Therapeutics shares last traded at $27.41, with a volume of 142,259 shares traded.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. B. Riley Financial boosted their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Roth Mkm reissued a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.36.

Capricor Therapeutics Stock Up 6.2%

The business’s 50 day moving average is $30.65 and its two-hundred day moving average is $27.74. The firm has a market capitalization of $1.60 billion, a P/E ratio of -11.89 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In related news, Director Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total transaction of $240,928.00. Following the sale, the director directly owned 7,529 shares in the company, valued at $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at approximately $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 172,529 shares of company stock worth $5,302,440. Company insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. Goldman Sachs Group Inc. raised its position in Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Legal & General Group Plc raised its position in Capricor Therapeutics by 8.4% in the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 3,205 shares in the last quarter. Rhumbline Advisers raised its position in Capricor Therapeutics by 7.3% in the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 3,636 shares in the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics in the second quarter worth about $796,000. Finally, Jump Financial LLC raised its position in Capricor Therapeutics by 42.6% in the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after acquiring an additional 69,515 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.